Research For better living

category: News item

CEO Hans van Veen has died

23 April 1964 – 22 July 2017

Hans van Veen, CEO of Triskelion and member of the First Dutch Innovations (FDI) management team, has died at the age of 53.
He inspired many with his energetic and professional style of management. In Hans we lose not only a valued and sincere director but also a man whose attitude was so unconventionally optimistic.
Hans leaves behind a wife and two sons.

You can leave a message in the condoleance register.

On 7 September 2017 a memorial service will be held for Hans. If you wish to receive an invitation for this, please mail yvette.estourgie@triskelion.nl.

Triskelion’s 6th TIM User Group Meeting in Amsterdam a great success

Last week the 6th edition of the TIM (TNO gastroIntestinal Model) User Group meeting took place in Amsterdam. The 2-day event was extraordinary for various reasons. First of all, we welcomed 50 guests from all over the globe, the highest attendance since the start of the event in 2009.

This year’s edition was also an anniversary, since it was 25 years ago that Rob Havenaar and Mans Minekus started to develop the first prototype of an in vitro gastro intestinal model, soon to be known as TNO’s Intestine Model, TIM.

And we proudly introduced our new generation TIM system, which is designed as an easy-to-use, robustly engineered, smart and highly predictive in vitro model.

Last, but certainly not least, the program had a great line-up of reputable speakers from both academia and industry, presenting their latest results in both pharmaceutical and food in vitro gastro-intestinal research.

Both the setting and the informal atmosphere in which the event took place contributed to an open stimulating exchange of ideas, experiences and results. The new TIM model was received with great enthusiasm and the festive launch concluded a highly successful event.

All in all, we are proud to be part of the community of TIM Users and we invite you to join in.

For more information, please contact us: martin.ham@triskelion.nl.

PRESS RELEASE: Triskelion begins major study of safety in chemicals

On behalf of an international REACH consortium, Triskelion will be undertaking its biggest ever assignment, namely an impressive study package aimed at guaranteeing human safety. The performance of these studies has been made compulsory by the European legislation on chemicals (REACH). This study package comprises two Prenatal Developmental Toxicity studies (OECD 414) with prior Dose Range Finding studies and an Extended One Generation Reproduction Toxicity Study (EOGRTS; OECD 443). The studies are worth a total of some two million euros.

Expertise, flexibility and planning are the primary reasons why Triskelion has been selected by the consortium of 18 global players to carry out this complex package of studies. Triskelion has a reputation for its excellent qualities in the field of inhalation toxicology and is convinced that it can complete this study package capably and on time. The timeline for the whole study package of around 19 months presents a fantastic logistical challenge.

About Triskelion
Triskelion – one of the 24 companies in the portfolio of First Dutch Innovations – is a growing Contract Research Organization (CRO) with around 200 employees serving clients from all over the world. Triskelion is the CRO for complex study packages and is active in the Chemical, Pharmaceutical, Food and Biotech industries. Specialization in multidisciplinary projects, consultancy skills, knowledge and personal attention all go towards creating client-specific study protocols and reliable project management.

For more information please feel free to contact Yvette Estourgie:
Phone number: +31 88 866 2727
E-mail address: mailto:yvette.estourgie@triskelion.nl